---
title: "Newland released its semi-annual performance, with a net profit attributable to the parent company of 78.03 million yuan, a year-on-year decrease of 30.01%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252441950.md"
description: "Newland released its 2025 semi-annual performance, with revenue of 359 million yuan, a year-on-year decrease of 9.57%; net profit attributable to shareholders of the parent company was 78.03 million yuan, a year-on-year decrease of 30.01%; net profit excluding non-recurring items was 71.79 million yuan, a year-on-year decrease of 31.56%; basic earnings per share were 0.20 yuan. Despite the overall decline in performance, revenue from toluenesulfonic acid increased by 13.16% year-on-year, and the company has competitive advantages in the pharmaceutical and high-purity markets, actively expanding into high-end application fields"
datetime: "2025-08-11T08:05:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252441950.md)
  - [en](https://longbridge.com/en/news/252441950.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252441950.md)
---

# Newland released its semi-annual performance, with a net profit attributable to the parent company of 78.03 million yuan, a year-on-year decrease of 30.01%

According to the Zhitong Finance APP, Newland (301277.SZ) disclosed its semi-annual report for 2025, reporting revenue of 359 million yuan, a year-on-year decrease of 9.57%; net profit attributable to shareholders of the listed company was 78.03 million yuan, a year-on-year decrease of 30.01%; net profit excluding non-recurring items was 71.79 million yuan, a year-on-year decrease of 31.56%; basic earnings per share were 0.20 yuan.

During the reporting period, revenue from toluenesulfonic acid increased by 13.16% year-on-year, mainly due to the company's strong competitive advantage in the pharmaceutical-grade and high-purity market, achieved through continuous technological research and development, process innovation, and an excellent quality management system. With the widespread use of toluenesulfonic acid in pharmaceuticals and high-end electronic chemicals, the company is actively expanding its market customers in high-end application fields and continuously increasing its market share in the high-end market

### Related Stocks

- [301277.CN](https://longbridge.com/en/quote/301277.CN.md)

## Related News & Research

- [IPO Winners & Losers Podcast: Cerebras, SpaceX, and the AI Takeover](https://longbridge.com/en/news/286957979.md)
- [Post Oak Energy Capital Announces Sale of UpCurve Energy Assets](https://longbridge.com/en/news/287062130.md)
- [Europe-China spacecraft launches to study Earth's 'invisible armour'](https://longbridge.com/en/news/286881963.md)
- [Assessing BlueNord (OB:BNOR) Valuation After Its US$400 Million Refinancing Deal](https://longbridge.com/en/news/287098111.md)
- [13:50 ETDimora Medical Launches Advanced Sacrum Silicone Absorbent Dressing to Enhance Pressure Injury Care](https://longbridge.com/en/news/287102270.md)